Evidence map›Paper›PMID 41588909›Full record

ArticlePsychiatry and clinical neurosciences2026

Response to "Clinical relevance of venlafaxine ER for generalized anxiety disorder".

Tempei Otsubo, Koichiro Watanabe, Takeshi Inoue, Ataru Inagaki, Toshiaki Kikuchi, Keisuke Nomoto, Shingo Higa, Yuko Asami, Bin Sun, Kristina Marschall

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Psychiatry and clinical neurosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tempei OtsuboDepartment of Psychosomatic and Psychiatric Medicine, Tokyo Women's Medical University Adachi Medical Center, Tokyo, Japan.ORCID https://orcid.org/0000-0002-0321-1714
Koichiro WatanabeDepartment of Neuropsychiatry, Kyorin University School of Medicine, Tokyo, Japan.ORCID https://orcid.org/0000-0002-0736-7070
Takeshi InoueDepartment of Psychiatry, Sapporo Hanazono Hospital, Sapporo, Japan.
Ataru InagakiAoyama Gakuin University, Department of Education, College of Education, Psychology and Human Studies/Health Administration Center, Tokyo, Japan.
Toshiaki KikuchiDepartment of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
Keisuke NomotoMedical Affairs, Viatris Pharmaceuticals Japan G.K, Tokyo, Japan.ORCID https://orcid.org/0000-0002-7469-2922
Shingo HigaMedical Affairs, Viatris Pharmaceuticals Japan G.K, Tokyo, Japan.
Yuko AsamiMedical Affairs, Viatris Pharmaceuticals Japan G.K, Tokyo, Japan.
Bin SunBiometrics, Data Management and Programming, Viatris Inc., Canonsburg, Pennsylvania, USA.
Kristina MarschallGlobal Clinical Sciences, Meda Pharma GmbH & Co. KG (a Viatris Company), Bad Homburg, Germany.

Funding

Viatris
6 · The paper itself

Abstract

This article relates to clinical relevance of venlafaxine ER for generalized anxiety disorder.

Indexed as

Generalized Anxiety DisorderSerotonin and Noradrenaline Reuptake InhibitorsVenlafaxine HydrochlorideDelayed-Action PreparationsHumansDelayed-Action PreparationsSerotonin and Noradrenaline Reuptake InhibitorsVenlafaxine Hydrochloride

Identifiers

PMID41588909
PMCPMC13060734

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.